Division of Cardiology, University of Turin, Turin, Italy.
Contemp Clin Trials. 2012 May;33(3):507-14. doi: 10.1016/j.cct.2012.01.001. Epub 2012 Jan 11.
Acute coronary syndromes (ACS) represent a difficult challenge for physicians. Risk scores have become the cornerstone in clinical and interventional decision making.
PubMed was systematically searched for ACS risk score studies. They were divided into ACS studies (evaluating Unstable Angina; UA, Non ST Segment Elevation Myocardial Infarction; NSTEMI, and ST Segment Elevation Myocardial Infarction; STEMI), UA/NSTEMI studies or STEMI studies. The c-statistics of validation studies were pooled when appropriate with random-effect methods. 7 derivation studies with 25,525 ACS patients and 15 validation studies including 257,654 people were formally appraised. Pooled analysis of GRACE scores, both at short (0.82; 0.80-0.89 I.C 95%) and long term follow up (0.84; 0.82-0.87; I.C 95%) showed the best performance, with similar results to Simple Risk Index (SRI) derivation cohorts at short term. For NSTEMI/UA, 18 derivation studies with 56,560 patients and 18 validation cohorts with 56,673 patients were included. Pooled analysis of validations studies showed c-statistics of 0.54 (95% CI = 0.52-0.57) and 0.67 (95% CI = 0.62-0.71) for short and long term TIMI validation studies, and 0.83 (95% CI = 0.79-9.87) and 0.80 (95% CI = 0.74-0.89) for short and long term GRACE studies. For STEMI, 15 studies with 134,557 patients with derivation scores, and 17 validation studies with 187,619 patients showed a pooled c-statistic of 0.77 (95% CI = 0.71-0.83) and 0.77 (95% CI = 0.72-0.85) for TIMI at short and long term, and a pooled c-statistic of 0.82 (95% CI = 0.81-0.83) and 0.81 (95% CI = 0.80-0.82) for GRACE at short and long terms respectively.
TIMI and GRACE are the risk scores that up until now have been most extensively investigated, with GRACE performing better. There are other potentially useful ACS risk scores available however these have not undergone rigorous validation. This study suggests that these other scores may be potentially useful and should be further researched.
急性冠脉综合征(ACS)对医生来说是一个极具挑战性的难题。风险评分已成为临床和介入决策的基石。
系统地在 PubMed 上搜索 ACS 风险评分研究。它们分为 ACS 研究(评估不稳定型心绞痛;UA、非 ST 段抬高型心肌梗死;NSTEMI 和 ST 段抬高型心肌梗死;STEMI)、UA/NSTEMI 研究或 STEMI 研究。当合适时,使用随机效应方法对验证研究的 C 统计量进行汇总。正式评估了 7 项具有 25525 例 ACS 患者的推导研究和包括 257654 人的 15 项验证研究。GRACE 评分的汇总分析,无论是短期(0.82;0.80-0.89 置信区间 95%)还是长期随访(0.84;0.82-0.87;置信区间 95%),均显示出最佳性能,与短期的简单风险指数(SRI)推导队列的结果相似。对于 NSTEMI/UA,纳入了 18 项具有 56560 例患者的推导研究和 18 项具有 56673 例患者的验证队列。对验证研究的汇总分析显示,短期和长期 TIMI 验证研究的 C 统计量分别为 0.54(95%CI=0.52-0.57)和 0.67(95%CI=0.62-0.71),短期和长期 GRACE 研究的 C 统计量分别为 0.83(95%CI=0.79-9.87)和 0.80(95%CI=0.74-0.89)。对于 STEMI,纳入了具有 134557 例患者推导评分的 15 项研究和具有 187619 例患者的 17 项验证研究,短期和长期 TIMI 的汇总 C 统计量分别为 0.77(95%CI=0.71-0.83)和 0.77(95%CI=0.72-0.85),短期和长期 GRACE 的汇总 C 统计量分别为 0.82(95%CI=0.81-0.83)和 0.81(95%CI=0.80-0.82)。
TIMI 和 GRACE 是迄今为止研究最多的风险评分,GRACE 表现更好。然而,还有其他一些潜在有用的 ACS 风险评分,但尚未经过严格验证。本研究表明,这些其他评分可能具有潜在的用途,应进一步研究。